证券代码：301239 证券简称：普瑞眼科 公告编号：2025-045 普瑞眼科医院集团股份有限公司 关于召开2025年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 普瑞眼科医院集团股份有限公司（以下简称"公司"或"本公司"）根据 第三届董事会第三十三次会议决议，决定于2025年11月04日（星期二）召开 2025年第一次临时股东会。现将本次股东会的有关事项公告如下： 一、召开会议的基本情况 1、股东会届次：2025年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创 业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司 章程》的有关规定。 4、会议时间： （1）现场会议时间：2025年11月04日15:30 提案2、3实行累积投票制进行表决，应选非独立董事3人，独立董事2人。 股东所拥有的选举票数为其所持有表决权的股份数量乘以应选人数，股东可以 将所拥有的选举票数以应选人数为限在候选人 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-042 普瑞眼科医院集团股份有限公司 （一）审议通过《关于调整董事会成员人数并修订<公司章程>及其附件的 议案》 为进一步提高公司董事会运作和决策效率，优化公司治理，根据《公司法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第2号——创业板上市公司规范运作》等法律法规及《公司章程》的有关规 定，结合公司实际情况，公司拟修订《公司章程》及其附件，将董事会成员人 数由7人调整为5人，其中独立董事人数由3人调整为2人。 董事会提请股东会授权相关工作人员负责办理本次工商变更登记、备案手 续等具体事项，授权的有效期限自股东会审议通过之日起至本次相关工商变更 登记及章程备案办理完毕之日止。 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于调整 董事会成员人数并修订<公司章程>及其附件的公告》及相关公告。 表决情况：同意7票，反对0票，弃权0票。 第三届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情 ...

10月10日，普瑞眼科涨0.87%，成交额5025.76万元。两融数据显示，当日普瑞眼科获融资买入额328.71 万元，融资偿还315.19万元，融资净买入13.52万元。截至10月10日，普瑞眼科融资融券余额合计 7078.43万元。 融资方面，普瑞眼科当日融资买入328.71万元。当前融资余额7012.85万元，占流通市值的1.27%，融资 余额低于近一年10%分位水平，处于低位。 截至6月30日，普瑞眼科股东户数1.06万，较上期增加6.24%；人均流通股6647股，较上期减少5.87%。 2025年1月-6月，普瑞眼科实现营业收入14.59亿元，同比增长2.74%；归母净利润1466.75万元，同比减 少66.12%。 分红方面，普瑞眼科A股上市后累计派现7450.74万元。 机构持仓方面，截止2025年6月30日，普瑞眼科十大流通股东中，融通健康产业灵活配置混合A/B （000727）位居第三大流通股东，持股259.25万股，相比上期增加69.24万股。圆信永丰聚优A （010469）位居第四大流通股东，持股176.68万股，为新进股东。博时医疗保健混合A（050026）位居 第九大流通股东，持股1 ...

Core Viewpoint - The announcement from Puri Eye Hospital indicates that its controlling shareholder, Chengdu Puri Century Investment Co., Ltd., has pledged part of its shares, specifically 1,900,000 shares [2] Company Summary - Puri Eye Hospital's controlling shareholder has engaged in a stock pledge transaction involving 1,900,000 shares [2]

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-041 普瑞眼科医院集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份质押的基本情况 普瑞眼科医院集团股份有限公司（以下简称"公司"）近日接到控股股东 成都普瑞世纪投资有限责任公司（以下简称"普瑞投资"）的通知，获悉普瑞 投资将其所持有的公司部分股份办理了股票质押业务。具体事项如下： | 是否 | 为控 | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 是 | 股股 | 否 | 质 | | | | | | | | | | | | | | | | 股 | 东或 | 质 | 为 | 本次质押 | 占其所 | 占公司 | 是否 | 质押 | 押 | 东 | 第一 | 质权 | 押 | | | | | | 补 ...

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-040 普瑞眼科医院集团股份有限公司 关于独立董事任期满六年辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 普瑞眼科医院集团股份有限公司（以下简称"公司"）董事会于近日收到 公司独立董事CHEN PENGHUI先生的书面辞职报告。CHEN PENGHUI先生自2019年9 月20日起担任公司独立董事，截至2025年9月19日，连续担任公司独立董事届满 六年。根据《上市公司独立董事管理办法》相关规定，CHEN PENGHUI先生特向 公司董事会申请辞去公司第三届董事会独立董事职务，同时辞去其在董事会薪 酬与考核委员会主任委员、战略委员会委员职务。辞职后，CHEN PENGHUI先生 将不再担任公司任何职务。截至本公告披露日，CHEN PENGHUI先生未持有公司 股份，不存在应当履行而未履行的承诺事项。 二〇二五年九月二十二日 鉴于CHEN PENGHUI先生的辞职将导致公司独立董事占董事会成员的比例低 于三分之一，董事会相关专门委员会中独立董事人数未达要求，为保证公司董 事会的规范运作 ...

国泰海通证券股份有限公司 关于普瑞眼科医院集团股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐人名称：国泰海通证券股份有限公司 | 被保荐公司简称：普瑞眼科 | | --- | --- | | 保荐代表人姓名：田卓玲 | 联系电话：13520345327 | | 保荐代表人姓名：李沁杭 | 联系电话：18526793477 | | 报告事项 | 说明 | | --- | --- | | | 是，2025 年 4 月 8 日，原保荐代表人朱玉峰 | | | 先生因工作安排原因，无法继续从事对公司 | | | 的持续督导工作。为保证持续督导工作的有 | | 1.保荐代表人变更及其理由 | 序进行，国泰海通现委派保荐代表人李沁杭 | | | 先生接替朱玉峰先生继续履行持续督导工 | | | 作。 | | | 原国泰君安证券股份有限公司（以下简称"国 | | | 泰君安"）换股吸收合并原海通证券股份有限 | | | 公司（以下简称"海通证券"）事项已获得中 | | | 国证券监督管理委员会核准批复，本次合并 | | | 交易已于 2025 年 3 月 14 日（即"交割日"） | | | 完成交割，自该日起 ...

Core Viewpoint - The company anticipates challenges in revenue growth across its business segments in Q2 2025 due to a slowdown in overall demand and intensified industry competition, particularly affecting its cataract project revenue [1] Group 1: Revenue and Performance - The company's revenue is expected to decline in Q2 2025, influenced by the centralized procurement policy for artificial lenses and reforms in medical insurance payment methods [1] - Despite the anticipated decline in Q2, the company expects stable overall revenue and operating cash flow in the first half of 2025 [1] Group 2: Industry Trends and Technological Advancements - Continuous advancements in ophthalmic medical technology, such as femtosecond-assisted cataract surgery and new techniques like all-laser 4.0 and all-laser pro, are expected to enhance treatment outcomes for patients [1] - These technological improvements may help optimize the company's business structure and elevate performance levels [1] Group 3: Management Outlook - The management expresses confidence in the company's long-term development despite the short-term challenges [1]

Core Viewpoint - The ophthalmology medical industry is experiencing a slowdown in the growth of refractive surgery revenue, with many companies reporting single-digit growth rates in this segment, while a few are still achieving double-digit growth. Group 1: Industry Overview - The refractive surgery business, a significant revenue source for private ophthalmology institutions, has shown a general trend of slowing growth in recent years [1] - Among five listed ophthalmology companies in A-shares, three reported refractive project revenue growth at single-digit levels or below in the first half of the year [1] - Specific growth figures include: - Puyi Eye Hospital (301239.SZ) with a 4.13% increase to 720 million yuan, accounting for 49% of total revenue [1] - He’s Eye Hospital (301103.SZ) with a 3.26% increase to 135 million yuan, accounting for 24% of total revenue [1] - Guangzheng Eye Hospital (002524.SZ) with a 0.32% increase to 142 million yuan, accounting for 32.71% of total revenue [1] - Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) are exceptions, achieving revenue growth rates of 11.4% and 13.75%, respectively [1] Group 2: Company Strategies - Aier Eye Hospital attributes its revenue growth in refractive projects to the acceptance of new surgical techniques such as All-Laser LASIK and the expansion of its medical network, enhancing patient coverage [3] - Puyi Eye Hospital is focusing on introducing authoritative expert teams and updating high-end diagnostic equipment to cultivate new growth points in the competitive refractive and vision care market [3] Group 3: Market Demand and Trends - The current refractive surgery patient population is divided into two categories: those with essential needs due to academic or professional requirements and those seeking aesthetic improvements [4] - Despite a stable demand from the essential needs group, the decision-making cycle for non-essential consumers is lengthening due to macroeconomic factors [4] - There is significant unmet demand in the refractive surgery market, with approximately 700 million myopic patients in China, but only about 1 million undergoing surgery annually [4] - The Z generation shows a personalized and urgent demand for vision correction, driving innovation and iteration in refractive surgery technologies [4] - Aierkon has introduced new refractive surgery solutions, such as All-Laser LASIK, which allows for personalized treatment based on various eye data [4] Group 4: Technology Adoption - Aierkon's All-Laser LASIK equipment has seen over 50,000 surgeries performed since its launch at the 2023 China International Import Expo, with over 100 hospitals equipped nationwide [5] - The company emphasizes the need for continued market education to enhance the penetration of new technologies [5]